$21.18 0.04 (+0.19%)
11/6/2009 4:00 PM

Crucell N.V. (ADR) (CRXL)

CAPS Rating: 4 out of 5

A fully integrated biopharmaceutical company, focuses on developing, producing and marketing vaccines and antibodies against infectious diseases for private and public markets worldwide and leverage its novel, proprietary technologies.

Current Price $21.18 Mkt Cap $1.41B
Open $0.00 P/E Ratio 0.00
Prev. Close $21.18 Div. (Yield) N/A (N/A)
Daily Range $20.98 - $21.39 Volume 480,577
52-Wk Range $11.29 - $25.53 Avg. Daily Vol. 461,000

CRXL News and Commentary

Caps

How do you think CRXL will perform vs the S&P 500?

Add Stock to Watchlist

All Members

122 Outperform
8 Underperform
 

All-Star Members

36 Outperform
3 Underperform
 

Wall Street

3 Outperform
0 Underperform
 

Top CRXL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

dropje (71.08)
Submitted December 08, 2006

Dutch pride; bit speculative but promising pipeline

0 Comments | Reply | Report this Post

brendatucker (< 20)
Submitted July 11, 2008

Do we really need another supplier of vaccines?

Avid Bioservices in California has contracted to distribute the vaccines, but Avid is owned by Peregrine (PPHM) a company whose stock is trading under $1. The most that can be hoped for with… More

0 Comments | Reply | Report this Post
CRXL VS S&P 500 (SPY)

Fools bullish on CRXL are also bullish on:

Fools bearish on CRXL are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about CRXL.

Recs

0
Member Avatar PoorUnemployed (< 20) Submitted: 10/23/2009 9:28:54 AM : Outperform Start Price: $21.31 CRXL Score: +1.72

CRXL has some of the best technology for making vaccines. Guess what? This is the era of vaccines! You hear about it everyday in the media. Target $28.00

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar delavida (< 20) Submitted: 10/17/2009 10:02:27 AM : Outperform Start Price: $21.36 CRXL Score: +0.94

Crucell is involved in every major vaccine program in the world including TB, malaria, HIV and ebola. In addition with it proprietary technology including PERc.6, AdVac and MabAbstract they are miles ahead of competitors. In addition with over 80 partners having clinical trials underway the royalty income should be substantial within the next 5 years. With the US government support and recent partnership with JNJ Crucell ,may turn the Flu vaccine business totally around with their Universal flu antibody and a possible universal flu vaccine. The company is grossly undervalues and under the radar and presently has over 600 million in cash

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar andcheese (74.79) Submitted: 9/4/2009 2:50:08 PM : Outperform Start Price: $22.02 CRXL Score: -9.43

Crucell, the seventh-largest vaccine maker in the world, sells the flu vaccine Inflexal. Mild flu seasons over the last two years have made it difficult for Crucell to grow its flu vaccine franchise. But if advance orders from competing firms are any indication, Crucell could increase its seasonal flu vaccine sales by at least 50% this year. That could translate to an extra, unexpected $40 million in revenue. For a firm with about $400 million in sales, that's no chump change.

Report this Post 0 Comments | Reply | Permalink
View All 24 Pitches »

Leaderboard

Find the members with the highest scoring picks in CRXL.

Score Leader

IndianaPwns

IndianaPwns (96.56) Score: +118.24

The Score Leader is the member with the highest score across all their picks in CRXL.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
TMFBreakerDave 98.02 10/10/2008 Outperform 3Y $10.50 +101.71% +26.69% +75.03 2 Comments
andrew1988 70.93 2/12/2008 8/15/2008 Outperform 1Y $13.45 +57.47% -17.45% +74.92
RUNNER71 < 20 10/21/2008 10/21/2009 Outperform 1Y $11.25 +88.27% +14.76% +73.50
hwyman64 96.18 10/21/2008 Outperform 5Y $11.55 +83.38% +13.32% +70.06
JPAHOME < 20 2/21/2008 Outperform 3M $14.30 +48.13% -17.87% +66.01 1 Comment
bxpspence 30.60 10/14/2008 Outperform 3M $12.42 +70.53% +4.97% +65.56
AntiNowhereDan 87.61 9/9/2008 Outperform 3Y $15.30 +38.43% -13.02% +51.45
pdt24 < 20 9/22/2008 Outperform 5Y $15.18 +39.53% -11.78% +51.31
hayrettin 78.73 7/9/2008 Outperform NS $15.67 +35.16% -13.30% +48.46
AvaMac < 20 1/2/2008 Outperform 3Y $17.13 +23.64% -23.81% +47.45 1 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackUBS 86.41 11/6/2009 Outperform NS $21.22 -0.19% +1.39% -1.58
TrackUBS 86.41 6/15/2009 Outperform NS $22.95 -2.14% +6.94% -9.07 8/20/2009 @ $22.46
TrackJefferies 75.83 2/12/2009 Outperform NS $20.59 +2.87% +32.68% -29.81
TrackNeedham < 20 11/14/2007 Outperform NS $19.07 +11.06% -24.78% +35.85

Featured Broker Partners